In This Article:
Over the last 7 days, the United States market has experienced a 2.6% drop, yet it has shown resilience with a 24% rise over the past year and earnings projected to grow by 15% annually. In this dynamic environment, identifying small-cap stocks that are potentially undervalued and exhibit insider action can offer unique opportunities for investors seeking to capitalize on emerging growth prospects.
Top 10 Undervalued Small Caps With Insider Buying In The United States
| Name | PE | PS | Discount to Fair Value | Value Rating |
|---|---|---|---|---|
| German American Bancorp | 14.5x | 4.8x | 47.99% | ★★★★☆☆ |
| Quanex Building Products | 34.5x | 0.9x | 37.92% | ★★★★☆☆ |
| ProPetro Holding | NA | 0.7x | 37.25% | ★★★★☆☆ |
| ChromaDex | 273.5x | 4.4x | 37.17% | ★★★☆☆☆ |
| Limbach Holdings | 36.7x | 1.9x | 43.41% | ★★★☆☆☆ |
| RGC Resources | 17.5x | 2.4x | 20.34% | ★★★☆☆☆ |
| Community West Bancshares | 18.7x | 2.9x | 42.25% | ★★★☆☆☆ |
| Tilray Brands | NA | 1.5x | -79.64% | ★★★☆☆☆ |
| Delek US Holdings | NA | 0.1x | -73.70% | ★★★☆☆☆ |
| Sabre | NA | 0.5x | -78.05% | ★★★☆☆☆ |
Let's review some notable picks from our screened stocks.
Celldex Therapeutics
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Celldex Therapeutics focuses on the development, manufacturing, and commercialization of novel therapeutics with a market cap of $1.51 billion.
Operations: Revenue primarily comes from the development, manufacturing, and commercialization of novel therapeutics. The company has experienced fluctuations in gross profit margin, with a notable trend reaching -13.74% in the latest period. Operating expenses have varied over time but recently stood at $37.12 million for the last reported period.
PE: -10.9x
Celldex Therapeutics, a small company in the biotech sector, has seen insider confidence with recent share purchases. Despite reporting a net loss of US$42.12 million for Q3 2024, revenue increased to US$3.19 million from US$1.52 million year-over-year. The company is advancing its pipeline with promising Phase 2 results for barzolvolimab and initiated Phase 1a trials for CDX-622 targeting inflammatory disorders, indicating potential growth avenues despite current unprofitability and high-risk funding sources.
Trinity Capital
Simply Wall St Value Rating: ★★★★★☆
Overview: Trinity Capital operates primarily in providing financial services related to blank checks, with a market capitalization of approximately $0.62 billion.
Operations: Trinity Capital generates revenue primarily from its blank checks segment. The company has consistently achieved a gross profit margin of 100%, with operating expenses and non-operating expenses impacting net income. Over recent periods, net income margins have shown variability, reaching as high as 43.98% and experiencing negative values at times.